SM
CLVS

Sabby Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Sabby Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-67
Closed -$456K – 198
2017
Q4 		$456K Sell
67
-1,045
-94% -$73.1K 0.04% 105
2017
Q3 		$9.16M Sell
1,112
-1,727
-61% -$137K 0.6% 23
2017
Q2 		$26.6M Sell
2,839
-413
-13% -$25.3K 1.74% 12
2017
Q1 		$20.7M Sell
3,252
-126
-4% -$7.66K 1.12% 17
2016
Q4 		$15M Sell
3,378
-2,472
-42% -$87K 0.87% 27
2016
Q3 		$21.1M Buy
5,850
+4,224
+260% +$90.6K 0.79% 26
2016
Q2 		$2.23M Sell
1,626
-236
-13% -$3.45K 0.12% 103
2016
Q1 		$3.58M Buy
1,862
+1,612
+645% +$34.1K 0.18% 60
2015
Q4 		$875K Buy
+250
New +$16.1K 0.05% 199
2014
Q3 		– Sell
-1,998
Closed -$8.27M – 307
2014
Q2 		$8.27M Buy
1,998
+67
+3% +$3.45K 0.35% 43
2014
Q1 		$13.4M Buy
1,931
+1,897
+5,579% +$139K 0.75% 33
2013
Q4 		$205K Buy
+34
New +$1.85K 0.01% 182

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sabby Management's CLVS Position: Q3 2017 in Review

Sabby Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 7,065 shares — an estimated $560K sold.

Sabby Management first reported a position in CLVS in Q2 2014 and held it in 5 quarters. The position peaked at $828K in Q2 2014. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

  • Sabby Management reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 7,065 Clovis Oncology, Inc. shares in Q3 2017, an estimated $560K.
  • Sabby Management first reported a position in Clovis Oncology, Inc. in Q2 2014 and held it in 5 quarters.
  • Sabby Management's Clovis Oncology, Inc. position peaked at $828K in Q2 2014.
  • 255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.